Bone Marrow & Stem Cell Transplant

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs allogeneic cell transplant in older patients with relapsed/refractory acute myeloid leukemia.

Efficacy findings from the phase 2 AGAVE-201 support the use of axatilimab, which was approved by the FDA for recurrent or refractory chronic graft-vs-host disease in August 2024.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed the evolving role of transplant in myelodysplastic syndromes.

Axatilimab is now an FDA-approved treatment option for patients with chronic graft-vs-host disease.

A phase 2 study found that a combination of pacritinib, sirolimus, and tacrolimus successfully suppressed pSTAT3 and Th1/Th17 cells, but failed to prevent acute graft-versus-host disease following allogeneic transplant.

Mayuko Sakae, MD, discussed research on pain management for patients undergoing bone marrow transplants, highlighting the potential buprenorphine shows in offering a valuable alternative to traditional opioids.

Patients who underwent hematopoietic cell transplantation had similar outcomes with matched vs mismatched unrelated donors when posttransplant cyclophosphamide was used.

The FDA has accepted and granted priority review to tab-cel, a treatment for Epstein Barr virus-positive posttransplant lymphoproliferative disease.

The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.

Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.

The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Neel Bhatt, MD, discussed the importance of long-term patient monitoring following hematopoietic cell transplantation.

The phase 3 SIERRA study revealed that only Iomab-B recipients achieved the primary end point of durable complete remission.

In a feature article incorporating Case-Based Roundtable® discussions, we look at the evolution of management for chronic graft-vs-host disease (cGVHD) following allogeneic hematopoietic cell transplantation and the impact of effective non-steroid therapies for cGVHD.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

Saad Z. Usmani, MD, MBA, FACP, FASCO, delves into the development of new treatments for patients with multiple myeloma.

Betty Hamilton, MD, discussed findings from a quality of life study in patients with FLT3 ITD-positive acute myeloid leukemia who underwent allogeneic stem cell transplant.

Chelsea Peterson, DO, discussed a real-world study investigating ruxolitinib in patients with steroid-refractory graft-vs-host disease.

Michael Scordo, MD, discussed findings from a phase 2 study investigating new antithymocyte globulin dosing models for ex vivo CD34-selected allogeneic stem cell transplants.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.

Jeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.

In an interview with Targeted Oncology, Chakra Chaulagain, MD, discussed the trends of higher rates of autologous hematopoietic stem cell transplantation refusal among patients with multiple myeloma.

Kayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.

Alice Bertaina, MD, discussed combining T-allo10 gene therapy with stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

The latest developments across the fields of stem cell transplantation and cellular therapy were presented at the 2024 Tandem Meetings in San Antonio, Texas, from February 21-24, 2024.